Sanofi stock holds steady as Berenberg reiterates Buy rating ahead of asthma drug data
Published on 08/24/2026 at 18:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi (FR0000127771) stock is trading steadily in the high €70s on Euronext Paris and mid-$40s on Nasdaq as of August 21, 2026, while analysts highlight upside linked to upcoming phase 2b data for an asthma treatment.
Analyst backs Sanofi ahead asthma trial data
Recent coverage on August 24, 2026 describes how a major European research house has confirmed a positive view on Sanofi shares with a Buy rating, keeping a price target of 105 EUR on the stock. This target stands well above the latest Paris closing price of 78.94 EUR, implying an upside of more than 30 EUR per share once converted into the same currency context. The same analyst overview notes that the average target for Sanofi stands at 94.28 EUR, which is 15.34 EUR above the last close and represents a spread of 19.43 percent versus that 78.94 EUR level. This gap between the current quote and average target underscores that, even after a mild year-to-date gain, analysts still see room for further appreciation.
In that August 24, 2026 note, the analyst commentary is tied to upcoming phase 2b trial results for an asthma drug candidate being co-developed by Sanofi. The reaffirmed Buy stance and 105 EUR target suggest confidence that the upcoming clinical data can support Sanofi’s longer-term growth in immunology and respiratory diseases. With the last close at 78.94 EUR and a high target at 105 EUR, the implied upside from this specific view is 26.06 EUR per share, giving investors a concrete sense of how much valuation could expand if the asthma program delivers on expectations.
Market performance in Paris and New York
On Euronext Paris, a recent real-time snapshot on August 24, 2026 shows Sanofi traded around 78.66 EUR intraday, modestly below the last official close of 78.94 EUR, representing a small intraday decline of 0.35 percent. A related quote table indicates that over the five prior trading sessions the stock slipped 0.35 percent, while from the start of 2026 it has gained around 2.3 to 2.5 percent, showing a cautious but positive year-to-date trajectory. The same dataset also reports a year-to-date change of between 2.30 percent and 2.52 percent, depending on the exact intraday reading, which means Sanofi has marginally outperformed a flat or slightly negative broader European healthcare backdrop.
In US trading, another market overview as of August 21, 2026 shows the Nasdaq-listed American depositary shares of Sanofi quoted at $45.85 at 4:00 p.m. Eastern Time. That close represented a daily gain of 0.70 points, or 1.55 percent, demonstrating a more pronounced move in the US session than in Paris on that day. The same analyst forecast page shows that, at that $45.85 close, the consensus twelve-month price target for Sanofi’s US shares sits at $49.50, with a high estimate of $50.00 and a low of $49.00. The average target of $49.50 implies a forecasted upside of 7.96 percent from the $45.85 reference price, signaling that the analyst community expects moderate capital appreciation rather than a dramatic re-rating.
The gap between the New York close of $45.85 on August 21, 2026 and the average target of $49.50 is $3.65 per share. While this upside is smaller than the EUR-based spread on Euronext Paris, it still represents tangible potential for investors seeking large-cap pharmaceutical exposure with a mix of defensive cash flows and targeted innovation bets. The combination of mid-single-digit expected upside in the US and roughly 19.43 percent upside relative to the average EUR target in Europe conveys that valuation perceptions differ slightly by market but share a common theme of cautious optimism.
Latest fundamental picture and consensus
The same forecast overview compiled from 15 equity research analysts provides useful context on how Sanofi’s fundamentals support those price targets. While individual revenue and earnings figures for the most recent quarter are not provided directly in that snippet, the fact that 15 separate research teams contribute to a consolidated twelve-month target suggests that Sanofi maintains a broad analyst following typical for a global top-tier pharmaceutical group. Consensus estimates usually integrate expectations for sales growth in key franchises such as vaccines, immunology, rare diseases, and consumer health, as well as margin trends and cash generation that underpin shareholder returns.
Within that forecast data as of August 23, 2026, analysts project upside of 7.96 percent from the current US price over the next year, as noted by the average target of $49.50 versus the $45.85 close. This projection factors in anticipated contributions from new products and ongoing efficiency programs. The high estimate of $50.00 only slightly exceeds the average, while the low estimate of $49.00 is just $0.50 below, indicating a narrow dispersion of views around the central scenario. Such a tight range often reflects a mature, predictable earnings base where analysts broadly agree on the earnings trajectory, rather than a binary outcome driven by a single high-risk clinical readout.
This consensus structure matters for investors because it shows that while the upcoming asthma phase 2b data could influence sentiment, the wider Sanofi story still rests on diversified revenue streams across multiple therapeutic areas. The analyst models underpinning the $49.50 average target likely assume continued performance in established products and measured investment into R&D, so any positive surprise from the asthma study may provide incremental upside relative to these already constructive but not aggressive expectations.
Asthma drug program as a growth driver
The asthma drug program highlighted in the August 24, 2026 commentary is one of several late-stage clinical assets that Sanofi is advancing in respiratory and immunology. Phase 2b trials are designed to refine dosing, efficacy, and safety signals ahead of potential phase 3 studies, which means the upcoming data will offer a more detailed picture of how well the therapy can manage asthma symptoms and exacerbations compared with existing standard treatments. For a company of Sanofi’s scale, a successful phase 2b outcome does not transform the entire investment case on its own, but it can meaningfully strengthen medium-term growth visibility in a strategically important disease area.
Investors will therefore pay close attention to how the phase 2b data affect projections for peak sales, pricing power, and competitive dynamics in the asthma segment. A strong set of results could justify higher revenue forecasts in analyst models, potentially leading to upward revisions of price targets beyond the current 94.28 EUR average in Europe and $49.50 average in the US. Conversely, weaker-than-expected data might prompt a recalibration of the upside implied by the 105 EUR high target. The reaffirmed Buy rating and maintained target ahead of the data release show that this particular analyst believes the risk-reward profile remains attractive, even with the clinical milestone still ahead.
Representative product: Sanofi’s asthma therapies
Sanofi’s broader respiratory and immunology portfolio includes asthma therapies that aim to reduce flare-ups, improve lung function, and enhance patients’ quality of life through biologic and small-molecule approaches. These products typically target specific pathways involved in airway inflammation, such as cytokines or immunoglobulin E, enabling more personalized treatment strategies for patients who do not respond adequately to conventional inhaled corticosteroids or bronchodilators. As the company develops new drug candidates and participates in phase 2b trials, it seeks to expand the range of options for physicians treating moderate-to-severe asthma.
For investors, the asthma franchise illustrates how Sanofi combines established therapeutic platforms with pipeline innovation to support its long-term growth story. Successful new launches in this area can broaden the revenue base, help offset patent expirations in older drugs, and reinforce the company’s positioning among global leaders in immunology and specialty care. The upcoming phase 2b asthma data mentioned in the August 24, 2026 analyst coverage will be an important checkpoint for assessing whether the latest candidate can join Sanofi’s roster of commercially meaningful respiratory products.
Sanofi stock levels and investor takeaways
In the US, Sanofi’s American depositary shares trade on Nasdaq, with the most recent fully closed session on August 21, 2026 showing a price of $45.85 at 4:00 p.m. Eastern Time. This level, combined with the $49.50 twelve-month consensus target, encapsulates the moderate upside that analysts factor into their models. In Europe, the last official close of 78.94 EUR on Euronext Paris provides a second anchor, against which the 94.28 EUR average target and 105 EUR high target signal more substantial potential appreciation. Across both markets, the spread between current prices and analyst targets reflects a view that Sanofi’s diversified portfolio, including upcoming asthma trial data, can sustain gradual value creation for shareholders.
Fact box
Company: Sanofi S.A.
ISIN: FR0000127771
Ticker: SNY
Exchange: Nasdaq, Euronext Paris
Price (as of August 21, 2026, 4:00 p.m. ET): $45.85 USD
Sector / Industry: Pharmaceuticals / Biotechnology
Index membership: CAC 40
